Photo by ehizelesamuel1 from unsplash
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways Click to show full abstract
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Keywords:
alkylating hdac;
edo s101;
inhibitor edo;
class alkylating;
hdac inhibitor;
first class
Journal Title: Blood Cancer Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Cancer Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!